STALLERGENES GREER - Key Persons
Job Titles:
- Chief Innovation Officer
- Executive Vice President Operations, Europe and International
Amer has extensive international experience in the pharmaceutical industry.
Prior to joining Stallergenes Greer as Executive Vice President Operations Europe in 2019, Amer Jaber was Head of Biotechnology Operations at R-Pharm where he was in charge of developing the long-term strategy and execution of in-house and external technical operations for CMC Development and Manufacturing. He was previously Head of Global Biotech Development and Manufacturing for Technical Operations and Managing Director of UCB Switzerland. Before joining UCB, he held roles of increasing responsibility in product development, quality and manufacturing at Mondobiotech, Serono International and Rivopharm.
He holds a PhD in Medicinal Organic Chemistry from the University of Geneva and has completed various executive leadership programs at Harvard Business School, IMD and Babson College.
Job Titles:
- WE BUILD TRUST WITH OUR STAKEHOLDERS EVERY DAY
The governance pillar of our corporate responsibility approach includes five key programme commitments which illustrate our commitment to maintaining the highest business standards and responsible business practices.
We are committed to conducting business with integrity, carrying out our operations in a responsible manner and we promote transparency and ethics in the way we do business.
Our corporate responsibility strategy is supported by our Executive Committee and our Board of Directors is regularly informed of its progress.
Job Titles:
- General Manager France and Global Head of Pricing
- General Manager France, Belgium and Luxembourg - Global Head of Pricing and Market Access
- in 2012 As Head of Strategy and Business Operations
- President of Stallergenes SAS, General Manager France and Belux
Dominique Pezziardi has been General Manager France and Global Head of Pricing and Market Access since 2018 and was appointed President of Stallergenes SAS in 2023. Dominique held roles of increasing responsibility in the pharmaceutical industry, holding positions in sales, marketing and strategy at...
Prior to joining Stallergenes Greer in 2012, Dominique Pezziardi gained his expertise in several therapeutic fields including fertility, growth hormones, diabetes, orphan diseases, cardiology and medical devices, within pharmaceutical companies including Ciba, Sanofi and Merck Serono.
He successfully managed global product launches, life cycle development plans, mature franchises relaunches, alliances with strategic partners or more recently, corporate strategy development.
He graduated from a business school in Bordeaux, France and trained in pharmaco-economy in Milano, Italy.
Dr. Giampiero De Luca is Head of Intellectual Property at B-FLEXION (formerly Waypoint Capital).
Prior to his appointment with B-FLEXION, Dr Giampiero De Luca was Vice President Licensing and Intellectual Property of Merck-Serono and Chief Intellectual Property Counsel of Serono International S.A. His responsibilities included management of Serono's patent portfolio, oversight of patent-related litigation and coordinating the Intellectual Property Department's support of the company's licensing activities.
Dr. De Luca began his career at the European Patent Office before joining Serono where he held a variety of positions and responsibilities including the management and coordination of research and development activities, and the establishment of the Corporate Intellectual Property Department in Geneva. Dr. De Luca was also a member of Serono's Executive Management Board.
He holds a doctoral degree in industrial chemistry from the University of Milan, a Diploma in General Microbiology from Institut Pasteur and is a chartered European Patent Attorney, Swiss and Italian Patent Attorney and authorised representative before the Office of Harmonisation in the Internal Market (OHIM).
Job Titles:
- Chief Medical Officer
- Medical Doctor
- VP and Head of the Intercontinental Region
Elena Rizova joined Stallergenes Greer in January 2024 as Chief Medical Officer with 22 years of international experience in the pharmaceutical industry
Elena has gained extensive expertise in drug development and the launch of new entities in dermatology, immunology, oncology, the central nervous system and infectious and cardiovascular diseases. Elena has significant leadership experience and has led complex cross-country matrix teams in medical, clinical, regulatory affairs, pharmacovigilance as well as in medical information and communication.
In her most recent role as VP and Head of the Intercontinental Region, Elena oversaw Biogen's medical teams and neuroscience portfolio based in Switzerland. She previously served as Global Head of Medical Affairs for Dermatology at Sanofi Genzyme based in the US. Prior to joining Sanofi Genzyme, Elena held several leadership roles at Johnson & Johnson Innovation Asia Pacific, Janssen based in Europe and Asia , 3M Pharmaceutical based in Europe and Galderma based in France.
Elena Rizova is a medical doctor and a board-certified dermatologist with a PhD in immunology.
Job Titles:
- Senior Vice President
- Senior Vice President Pharmaceutical Operations
Julien Storaï joined Stallergenes Greer as Senior Vice President Pharmaceutical Operations in 2023.
With more than 20 years of experience in the pharmaceutical industry, Julien Storaï was previously Chief Technical Officer at OM Pharma in Geneva (Switzerland), where he oversaw global industrial activities and was responsible for assuring the company's internal and external long-term industrial strategy. He also held site head and manufacturing positions at Vifor Pharma and began his professional career at Sanofi in Vaccine Industrial Development.
Julien Storaï holds a PhD in Industrial Microbiology, Biochemistry Engineer INSA (France), an MBA EM Lyon (France) and is certified Black Belt Six Sigma.
Job Titles:
- Senior Vice President, Human Resources
- in 2014 As Senior Vice President Human Resources, Europe
Jérôme Tilly joined Stallergenes Greer in 2014 as Senior Vice President Human Resources, Europe and International.
He previously worked at Sogefi, an Italian automotive supplier, where he served as Vice President Human Resources. Throughout his career, he held positions of increasing responsibility and gained in-depth knowledge of human resources at automotive, airport ground handling and media companies. Jérôme Tilly holds a master's degree in business administration, employment law and Human Resources from Paris Dauphine University, France
Job Titles:
- Chief Executive Officer
- Executive
Michele Antonelli has been CEO of Stallergenes Greer since January 2019. He joined the company in 2015 as Head of Europe and International. Previously, Michele Antonelli held roles of increasing responsibility and scope at UCB, most recently serving as EVP and Head of lmmunology Europe, overseeing the region's commercial, medical, and market access activities. Prior to UCB, Michele Antonelli spent 16 years at Merck Serono, ultimately serving as SVP and Global Head of Biotech Manufacturing and Process Development.
Michele Antonelli is Swiss and Italian.
Michele Antonelli is a seasoned biopharmaceutical executive with extensive expertise in both manufacturing and commercial activities.
Michele Antonelli previously worked at UCB where he held roles of various responsibility and scope, most recently serving as Executive Vice President and Head of lmmunology Europe, overseeing the region's commercial, medical, and market access activities.
Prior to joining UCB, Michele Antonelli spent 16 years at Merck Serono, ultimately serving as Senior Vice President and Global Head of Biotech Manufacturing and Process Development.
He is Swiss and Italian, and graduated as Doctor in Sciences from University of Bari. He trained in Biotechnology at Catholic University in Piacenza and at Iowa State University in Ames, Iowa.
Job Titles:
- Chief Financial Officer
- in 2017 As Head of Finance
Nicola Lamacchia joined Stallergenes Greer in 2017 as Head of Finance for the Europe and International region. Prior to joining Stallergenes Greer, he was Head of Finance for International at Shire, leading the creation of a new financial framework and supporting the company's growth and expansion. Prior to Shire, Nicola Lamacchia held several country, regional and divisionlevel financial roles at Merck Serono.
Nicola joined Stallergenes Greer in March 2017 as Head of Finance for Europe and International with a long-standing experience as business partner in biotechmanufacturing and commercial management.
Prior to joining Stallergenes Greer, he was Head of Finance for International at Shire, leading the creation of a new financial framework and supporting the company's growth and expansion.
Prior to Shire, he held several country, regional and division-level financial roles at Merck Serono, including Head of Divisional Controlling for the Neurology, Fertility and Endocrinology business, Head of Commercial Europe Finance, Global Biotech Manufacturing Controller, Finance and Logistic Director.
He is Swiss and Italian and holds a Master's Degree in Business and Economics from the Bocconi University in Milan, and a Business and Leadership Program MBA from MIT-Sloan.
Petr Tor - Chief Commercial Officer, EVP
Job Titles:
- Chief Commercial Officer
- Executive Vice President
- in 2010 As General Manager
- Senior Vice President, Commercial Operations, Europe and International
Petr Tor joined Stallergenes Greer in 2010 with significant international experience in the pharmaceutical industry, holding positions in finance, marketing and sales at local and regional levels.
Petr Tor gained his expertise in several therapeutic fields including asthma, cardio, diabetes, glaucom, antibiotics, antifungals and HIV within Merck & Co. known as MSD in Europe, where he spent 16 years.
He joined Stallergenes Greer as General Manager of the Czech and Slovak subsidiary and since 2014 he held commercial responsibilities for various regions with growing scope and complexity in Europe, Middle East and Africa.
He is Czech, graduated from Chemistry at Institute of Chemical Technology in Prague and got diploma in Accounting and Finance at MBA Rochester Institute of Technology, New York US Business School in Prague.
Job Titles:
- Chairman
- Vice - Chairman and Non - Executive Member of the Board of the B - FLEXION
Stefan Meister is Vice-Chairman and non-executive member of the Board of the B-FLEXION (formerly Waypoint Capital) , a business enterprise for the managers and advisers of the funds and investments associated with the Bertarelli family.
Before taking up this role at the start of 2021, he spent close to a decade as Waypoint's Group Chief Operating Officer.
Prior to that, he was Chief Financial Officer of the Haniel Group, before which he was a member of the Executive Management Board of Celesio Group. He began his career in 1991 at Novartis AG (Switzerland), holding various positions including Head of Controlling for the Pharma Division. Stefan Meister is a Member of the Advisory Board of the Centre for Leadership and Value in Society at the University of St. Gallen, a Member of the "Schweizer Dialog" and an active member of the World Economic Forum's Family Business Community. Until May 2016, he was a Member of the Board of Directors of the Swiss group, Straumann. Stefan Meister is Swiss and holds a degree in economics from Basel University
Job Titles:
- Executive Vice President, Head of Americas
- in 2016 As Global Head of Technical Operations
Tibor Nemes has a proven track record in the biotech and pharmaceutical industry in both Europe and in the United States. He has held leadership roles in engineering, process development, quality assurance and the manufacturing of biologics, solids, and sterile dosage forms.
Tibor joined Stallergenes Greer in 2016 as Global Head of Technical Operations before taking over as Head of the Americas in May 2018.
He previously spent eight years at Novartis where he held roles of increasing responsibility, most recently as the Global Operations Head, Tech Ops Manufacturing, Strategy and BDM&A where he headed Operations for Manufacturing Strategy and Business Development & Licensing within Global Technical Operations.
Prior to Novartis, Tibor Nemes held Engineering and Operations leadership roles at pharmaceutical and biotechnology companies including Novavax, Inc., Bristol-Myers Squibb Company, Elan Pharmaceuticals and Hypex, Inc.
Job Titles:
- General Counsel
- in 2017 As Associate General Counsel Europe
Valérie Benhamou has more than 20 years of experience in pharmaceutical and medical device law. Valérie joined Stallergenes Greer in 2017 from Abbott, where she was Senior Legal Counsel for France, Benelux and Africa.
Prior to Abbott, Valérie Benhamou served as Senior counsel for Bristol-Myers Squibb where she provided legal support to all divisions in France and to EMEA commercial operations. Earlier in her career, she practiced at law firms and focused on healthcare matters, including medical liability litigation and intellectual property. Valerie holds a master's degree in Private law and a postgraduate diploma in Intellectual Property law from the University of Paris II Panthéon-Assas. She has been a member of the Paris Bar since 1999.